摘要
Chronic Hepatitis C (HCV) infection is the leading indication for orthotopic liver transplantation and recurrence is nearly universal.Chronic HCV infection is frequently established through evasion of the innate immune system.Priming of adaptive immune responses modulate the severity and rate of fibrosis progression.Those with demonstrable viremia entering the transplant period uniformly suffer recurrence post-transplant.Progression to cirrhosis is accelerated posttransplant secondary to systemic immunosuppression.In addition,a number of factors,including donor,host,and viral characteristics,influence severity and rate of fibrosis progression.Interferon-based therapy,the previous standard of care,in those with advanced cirrhosis or post-transplant has been limited by a number of issues.These include a relative lack of efficacy and poor tolerability with higher incidence of infection and anemia.Recently,approval of direct acting antivirals have ushered in a new era in HCV therapeutics and have applicability in these special populations.Their use immediately prior to or post-transplant is expected to improve both morbidity and mortality.
